Bio-IT World January 12, 2023
Illumina President and CEO Francis deSouza kicked off his annual J.P. Morgan Healthcare Conference presentation highlighting the breadth of the genomics market. deSouza sees a $120 billion total addressable market for Illumina comprising oncology testing, genetic disease testing, reproductive health, and research, with oncology testing representing more than half of the opportunity. Currently, he said, the total market is 7% penetrated, leaving ample opportunity for Illumina’s vision of making genomics the standard for clinical care.
And Illumina is uniquely positioned, deSouza argued, touting more than 9,500 customers in 155 countries and an install base of 23,000 sequencing instruments. In 2022, the company is expecting $4.5 billion in revenue (Q4 audited results come in early February), more...
Today's Sponsors
Today's Sponsor